Oric Pharmaceuticals, Inc.
ORICNasdaqCIK 1796280HealthcareFiscal year ends Dec 31
Reports and events: 108 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2308:00 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-429465 |
| 2026-08-0320:20 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-330631 |
| 2026-08-0320:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-330568 |
| 2026-07-3020:49 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-326309 |
| 2026-06-2220:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-277511 |
| 2026-05-0420:20 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-204047 |
| 2026-05-0420:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-203993 |
| 2026-04-2820:03 ET | DEF 14A | Proxy statementPeriod 2026-06-18 | 0001193125-26-186911 |
| 2026-03-3120:16 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-134618 |
| 2026-02-2322:06 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-064291 |
| 2026-02-2321:15 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-064005 |
| 2026-02-2321:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-063974 |
| 2025-12-0811:02 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-310472 |
| 2025-11-1321:25 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-280247 |
| 2025-11-1321:20 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-280234 |
| 2025-11-1321:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-280196 |
| 2025-08-1420:05 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000950170-25-108850 |
| 2025-08-1220:20 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-107359 |
| 2025-08-1220:10 ET | 8-K | 2.02 Results of operations; 2.05 Exit or disposal costs; 9.01 Financial statements and exhibits | 0000950170-25-107313 |
| 2025-06-1320:05 ET | 8-K | 5.07 Shareholder vote results | 0001193125-25-140725 |
| 2025-06-0521:17 ET | SCHEDULE 13D | Ownership report, active investor | 0000950170-25-082520 |
| 2025-05-2820:42 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-129531 |
| 2025-05-0520:20 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-063564 |
| 2025-05-0520:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-063540 |
| 2025-04-2320:06 ET | DEF 14A | Proxy statementPeriod 2025-06-11 | 0001193125-25-091359 |
| 2025-03-1420:02 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-25-054784 |
| 2025-02-2521:34 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-035203 |
| 2025-02-1821:20 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-022273 |
| 2025-02-1821:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-022219 |
| 2025-01-1313:30 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-005028 |
| 2024-11-1221:20 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-125471 |
| 2024-11-1221:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-125386 |
| 2024-08-1220:20 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-095467 |
| 2024-08-1220:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-095419 |
| 2024-06-1420:05 ET | 8-K | 5.07 Shareholder vote results | 0001193125-24-161593 |
| 2024-05-0620:20 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-053582 |
| 2024-05-0620:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-053551 |
| 2024-04-2420:06 ET | DEF 14A | Proxy statementPeriod 2024-06-12 | 0001193125-24-110069 |
| 2024-03-2920:15 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-24-082077 |
| 2024-03-1120:20 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-029298 |
| 2024-03-1120:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-029239 |
| 2024-01-2214:01 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-011747 |
| 2024-01-0914:00 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-004909 |
| 2023-12-1121:05 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-292551 |
| 2023-11-0621:20 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-059415 |
| 2023-11-0621:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-059392 |
| 2023-10-2320:07 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-260795 |
| 2023-08-1020:20 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0000950170-23-041362 |
| 2023-08-1020:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-041326 |
| 2023-06-2710:05 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-23-175501 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.